mMe: Motivational Monitoring to Enhance Smoking Cessation Among Cancer Patients
Recruiting
The objectives of this study are to pilot test a protocol of weekly assessments of motivation to quit and other relevant constructs combined with information about how to enroll in cessation programs, which will allow initial quantification of motivation to quit during cancer treatment and develop hypotheses about the impact of motivation on the decision to enroll in services.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: University of Virginia Cancer Center and affiliated sites, Charlottesville, Virginia
Conditions: Smoking Behaviors, Cancer, Motivation
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
Recruiting
The goal of this clinical trial is to test CPO301, a type of drug called an antibody drug conjugate in adult patients with advanced or metastatic solid tumors. The main questions it aims to answer are: To assess the safety and tolerability of CPO301 at increasing doses and determine the dose to be used in the second part of the study (Part A) To assess the safety and tolerability of CPO301 at the dose determined to be safe and tolerable in Part A in patients with Non-Small Cell Lung Cancer and... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/10/2023
Locations: NEXT Virginia, Fairfax, Virginia
Conditions: Cancer, Cancer, Lung
Comprehensive Tobacco Cessation for Cancer Patients and Survivors
Recruiting
The purpose of this research study is to learn how best to incorporate tobacco cessation treatment into clinical care for cancer patients, survivors, and caregivers.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2023
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Tobacco Use Cessation, Cancer
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
Recruiting
This is a randomized trial of intensified post-discharge surveillance (Intervention Arm) versus standard post-discharge surveillance (Control Arm).
Gender:
All
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania
Conditions: Surgery, Cancer
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
Recruiting
This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or comparator agent(s) during participation in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and who do not have access to the study treatment locally, may continue to receive study treatment in this extension study following roll-over from the parent study.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: Univ of Alabama at Birmingham; UAB Comprehensive Cancer Ctr, Birmingham, Alabama +185 locations
Conditions: Cancer
Evaluation of Late Effects and Natural History of Disease in Patients Treated With Radiotherapy
Recruiting
Background: This protocol acknowledges that it is in the interest of the NIH and ROB, as well as our patients, to continue to follow those who have been treated with radiotherapy at ROB and are not otherwise eligible for current active research protocols. It also provides a mechanism for the correlation and interpretation of disparate data for research into the long term side effects and outcomes for a variety of disease entities and treatments, such as combined modality treatment, MoAb, PDT, r... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Cancer
Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC
Recruiting
This study is being done to understand how many people with HIV (PWH) present for cancer care across the AIDS Malignancy Consortium in the United States and if there are reasons that some PWH choose to participate, or not in cancer clinical trials. Optional quality of life surveys will be used to learn more about how HIV and cancer and HIV and cancer treatment affect people.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Moores UCSD Cancer Center, La Jolla, California +6 locations
Conditions: HIV-Associated Malignant Neoplasm, HIV Infections, Cancer, AIDS Related Lymphoma, AIDS-related Kaposi Sarcoma, AIDS-Related Malignancy, Anal Cancer, HPV-Related Malignancy
Evaluating a Pharmacogenetic Testing Panel in Patients Suspected to be at Increased Risk for Pharmacogenetics-related AEs While Receiving Fluoropyrimidine or Irinotecan Therapy
Recruiting
This study will be evaluating patients suspected to carry DPYD or UGT1A1 variants based off of Michigan Genomics Initiative (MGI) results. Standard of care treatment will be initiated with either Fluoropyrimidine or Irinotecan therapy. Retrospective collection of treatment related AEs and SAEs, dose delays, dose reductions, and treatment discontinuations will be completed.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Conditions: Cancer
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
Recruiting
This is a single-arm Phase II study to measure the impact of Molecular Tumor Board treatment recommendations on treatment decision-making in clinical practice at the Dartmouth Cancer Center. Following tumor genetic profiling, subjects will be screened for eligibility. Eligible subjects' cases will be evaluated by the Dartmouth Cancer Center Molecular Tumor Board, and treatment recommendations will be entered into the medical record as per standard procedure. The primary endpoint is a survey res... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Cancer
Testicular Tissue Cryopreservation in Children
Recruiting
This protocol is being designed to offer testicular tissue cryopreservation to male pediatric patients (0-17 years of age) with fertility threatening medical diagnoses or facing surgery, chemotherapy or radiation therapy that may cause loss of reproductive potential.
Gender:
Male
Ages:
Between 0 years and 17 years
Trial Updated:
11/27/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Cancer
Characterizing Fatigue Experienced by Cancer Patients Receiving Primary Treatment and Cancer Survivors
Recruiting
Background: - Fatigue is a common side effect of cancer and its treatment. Up to 96% of patients with cancer have fatigue. The cause of fatigue in people with cancer or those receiving treatment is poorly understood, making fatigue hard to treat. More research is necessary to understand why cancer patients experience fatigue. Previous research has shown that fatigue may be caused by a number of factors, including problems with the immune system response of the body while undergoing cancer treat... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
11/23/2023
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Cancer, Fatigue, Prostate Cancer, Breast Cancer, Cancer Survivor
Connect for Cancer Prevention Study (Connect)
Recruiting
Background: The National Cancer Institute, part of the National Institutes of Health, has partnered with nine health care systems across the U.S. to establish the Connect for Cancer Prevention Study. While researchers have made important discoveries, there is more to learn to lower the number of people affected by cancer. By taking part in Connect, participants can help researchers learn how the way we live, our genetics, and our health history may affect cancer risk. Objective: To study and... Read More
Gender:
All
Ages:
Between 40 years and 65 years
Trial Updated:
11/23/2023
Locations: Kaiser Permanente Colorado, Denver, Colorado +9 locations
Conditions: Cancer, General Research Use